GSK - GlaxoSmithKline plc

NYSE - NYSE Delayed Price. Currency in USD
44.50
+0.17 (+0.38%)
At close: 4:01PM EST

44.07 -0.43 (-0.97%)
Pre-Market: 8:15AM EST

Stock chart is not supported by your current browser
Previous Close44.33
Open44.63
Bid44.00 x 3000
Ask43.97 x 2200
Day's Range44.29 - 44.70
52 Week Range36.41 - 46.01
Volume2,155,577
Avg. Volume2,404,201
Market Cap110.909B
Beta (3Y Monthly)0.41
PE Ratio (TTM)44.86
EPS (TTM)0.99
Earnings DateFeb. 1, 2017 - Feb. 6, 2017
Forward Dividend & Yield1.96 (4.41%)
Ex-Dividend Date2019-11-14
1y Target Est46.33
  • India Plans Incentives to Bring In Foreign Manufacturers From Tesla to Glaxo
    Bloomberg

    India Plans Incentives to Bring In Foreign Manufacturers From Tesla to Glaxo

    (Bloomberg) -- Terms of Trade is a daily newsletter that untangles a world embroiled in trade wars. Sign up here. India is planning to offer 324 companies including Tesla Inc. and GlaxoSmithKline Plc incentives to set up factories in the South Asian nation in a bid to capitalize from the trade war between China and the U.S., according to a document seen by Bloomberg.The government proposes to provide the manufacturers land to set up a factory along with power, water and road access, according to draft of the document prepared by the Department for Promotion of Industry and Internal Trade and Invest India. Other companies that officials will reach out to include Eli Lilly & Co., South Korea’s Hanwha Chemical Corp., and Taiwan’s Hon Hai Precision Industry Co.While the trade war has benefited countries such as Vietnam and Malaysia, rigid land acquisition rules and labor laws have prompted investors to largely ignore India when looking for alternatives to China. The latest proposal may reduce red tape, and set the nation, which expanded at the slowest pace in six years last quarter, on a path to double its gross domestic product to $5 trillion by 2025 -- a goal set Prime Minister Narendra Modi.“While in the initial leg of relocation we have seen companies moving to Vietnam, I don’t think it is too late for India to start making an effort,” said Sonal Varma, chief economist for India and Asia-ex Japan at Nomura Holdings Inc. in Singapore. “India offers a unique advantage of being a huge domestic market too, so it is definitely an opportunity for the government to attract investment.”Under the plan, the government will create a land bank for ready-to-move-in industrial clusters, offer investment and location-based incentives and rationalize anti-dumping duties. The proposal includes incentives for plug-in and hybrid vehicles, fuel efficiency and carbon taxation. For the electronics and telecom sector, flexible employment, manufacturing-related incentives linked to investments and value addition have been sought.The country has made progress, rising 37 spots since 2017 in the World Bank’s ranking for ease of doing business, but it still comes in at 63rd, trailing not only China, but also Rwanda and Kosovo. At present, investors keen on setting up a factory need to acquire land on their own which, in some cases, involves a time consuming process of negotiating with small plot owners to part with their holding.The Prime Minister’s Office is considering the proposal and a decision is expected soon. An email sent to the spokeswoman at the commerce and industry ministry wasn’t immediately answered.Asia’s third-largest economy expanded 5% in the June quarter, with slew of data pointing to weaker economic activity.Getting investment inflows and boosting exports is therefore high on economic agenda of the government. It has already slashed corporate tax rate, making it competitive with rest of Asia, and has relaxed foreign investment rules to attract fund inflows in the country.(Updates with economist’s comment in fourth paragraph)To contact the reporter on this story: Shruti Srivastava in New Delhi at ssrivastav74@bloomberg.netTo contact the editors responsible for this story: Arijit Ghosh at aghosh@bloomberg.net, Unni KrishnanFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.

  • Novo Nordisk Inks Deal With Dicerna to Develop RNAi Therapies
    Zacks

    Novo Nordisk Inks Deal With Dicerna to Develop RNAi Therapies

    Novo Nordisk (NVO) inks deal with Dicerna Pharmaceuticals to discover and develop novel therapies for the treatment of liver-related cardio-metabolic diseases.

  • Roche Gets CHMP Opinion for Breast Cancer & Lymphoma Drugs
    Zacks

    Roche Gets CHMP Opinion for Breast Cancer & Lymphoma Drugs

    Roche's (RHHBY) breast cancer candidate and lymphona candidate get positive CHMP opinion. The company inks a deal to acquire Promedior, Inc.

  • Here's Why AstraZeneca's (AZN) Shares Are Up Year to Date
    Zacks

    Here's Why AstraZeneca's (AZN) Shares Are Up Year to Date

    AstraZeneca's (AZN) stock is on an upward trajectory this year. Let us take a look at the reasons for the same.

  • AstraZeneca/Merck's Selumetinib NDA Gets FDA Priority Status
    Zacks

    AstraZeneca/Merck's Selumetinib NDA Gets FDA Priority Status

    The FDA grants priority review to AstraZeneca (AZN) and Merck's NDA for MEK 1/2 inhibitor, selumetinib. Additionally, Qtrilmet tablets to treat type-II diabetes get approval in the EU.

  • Should Value Investors Buy GlaxoSmithKline (GSK) Stock?
    Zacks

    Should Value Investors Buy GlaxoSmithKline (GSK) Stock?

    Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

  • Pharma Stock Roundup: MRK, GSK, ABBV, LLY's Pipeline & Regulatory Updates
    Zacks

    Pharma Stock Roundup: MRK, GSK, ABBV, LLY's Pipeline & Regulatory Updates

    Merck (MRK) gets approval in Europe for Ebola vaccine. Roche, Glaxo (GSK) & Pfizer (PFE) provide pipeline updates.

  • 4 Big Drugmakers to Bet on After a Great Earnings Season
    Zacks

    4 Big Drugmakers to Bet on After a Great Earnings Season

    Big drugmakers post better-than-expected Q3 results, leading to rise in share price of most of the companies in the industry.

  • Glaxo's Nucala Meets Goal in Rare Inflammatory Disorder Study
    Zacks

    Glaxo's Nucala Meets Goal in Rare Inflammatory Disorder Study

    GlaxoSmithKline's (GSK) late-stage study evaluating Nucala succeeds in reducing flares in patients with Hypereosinophilic Syndrome.

  • Merck's Ebola Vaccine Gets Conditional Approval in Europe
    Zacks

    Merck's Ebola Vaccine Gets Conditional Approval in Europe

    European Commission grants approval to Merck's (MRK) Ervebo (V920) for active immunization of individuals 18 years and above to protect against Ebola Virus Disease caused by Zaire Ebola virus.

  • Novartis' Generics Unit to Buy Aspen's Japanese Operations
    Zacks

    Novartis' Generics Unit to Buy Aspen's Japanese Operations

    Novartis (NVS) inks a deal to acquire the Japanese business of Aspen Global Incorporated.

  • Need To Know: GlaxoSmithKline plc (LON:GSK) Insiders Have Been Selling Shares
    Simply Wall St.

    Need To Know: GlaxoSmithKline plc (LON:GSK) Insiders Have Been Selling Shares

    We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly...

  • Teva (TEVA) Q3 Earnings Miss, Stock Up on Guidance Increase
    Zacks

    Teva (TEVA) Q3 Earnings Miss, Stock Up on Guidance Increase

    Teva Pharmaceutical (TEVA) misses earnings estimate but beats the same for sales. The company increases the lower end of its 2019 sales and earnings guidance. Shares rise.

  • Emergent (EBS) Beat Earnings in Q3, Vaccines Drive Sales
    Zacks

    Emergent (EBS) Beat Earnings in Q3, Vaccines Drive Sales

    Emergent (EBS) rides high on both earnings and revenues beat in the third quarter. ACAM2000 and Narcan drive revenues.

  • Theravance (TBPH) Q3 Loss In Line, Revenues Lag Estimates
    Zacks

    Theravance (TBPH) Q3 Loss In Line, Revenues Lag Estimates

    Theravance's (TBPH) third-quarter loss matches estimates while revenues miss the same in absence of product sales due to the sale of its only marketed drug Vibativ to Cumberland Pharmaceuticals.

  • Agenus (AGEN) Q3 Earnings Beat Estimates, Revenues Up Y/Y
    Zacks

    Agenus (AGEN) Q3 Earnings Beat Estimates, Revenues Up Y/Y

    Agenus (AGEN) posts narrower-than-expected loss and beats sales estimates in the third quarter of 2019.

  • Value Biotech ETFs & Stocks to Buy Now
    Zacks

    Value Biotech ETFs & Stocks to Buy Now

    Biotech valuation looks attractive amid a volley of good news. Investors can tap these stocks and ETFs.

  • Drug/Biotech Stocks Nov 5 Earnings Roster: AGN, REGN & More
    Zacks

    Drug/Biotech Stocks Nov 5 Earnings Roster: AGN, REGN & More

    Let us take a look at five drug/biotech companies, which are supposed to release their quarterly results on Nov 5.

  • The Zacks Analyst Blog Highlights: Pfizer, Merck, Bristol-Myers and Glaxo
    Zacks

    The Zacks Analyst Blog Highlights: Pfizer, Merck, Bristol-Myers and Glaxo

    The Zacks Analyst Blog Highlights: Pfizer, Merck, Bristol-Myers and Glaxo

  • Dr. Reddy's (RDY) Q2 Earnings and Revenues Increase Y/Y
    Zacks

    Dr. Reddy's (RDY) Q2 Earnings and Revenues Increase Y/Y

    Dr. Reddy's (RDY) earnings and revenues increase year over year in second-quarter fiscal 2020.

  • Novo Nordisk (NVO) Q3 Earnings Beat Estimates, Revenues Miss
    Zacks

    Novo Nordisk (NVO) Q3 Earnings Beat Estimates, Revenues Miss

    Novo Nordisk (NVO) beats earnings estimates but misses sales estimates in the third quarter of 2019.

  • Pharma Stock Roundup: MRK, PFE, GSK, BMY Q3 Earnings, Other Updates
    Zacks

    Pharma Stock Roundup: MRK, PFE, GSK, BMY Q3 Earnings, Other Updates

    Pfizer (PFE), Merck (MRK), Bristol-Myers (BMY) and others release Q3 results.

  • What's in the Cards for Perrigo (PRGO) This Earnings Season?
    Zacks

    What's in the Cards for Perrigo (PRGO) This Earnings Season?

    Perrigo's (PRGO) Consumer Self Care Americas segment is expected to have aided the company's top line in the soon-to-be reported quarter.

  • Bristol-Myers (BMY) Hits Fresh High: Is There Still Room to Run?
    Zacks

    Bristol-Myers (BMY) Hits Fresh High: Is There Still Room to Run?

    Bristol-Myers (BMY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

  • Glaxo (GSK) Beats Q3 Earnings Estimates, Raises '19 EPS View
    Zacks

    Glaxo (GSK) Beats Q3 Earnings Estimates, Raises '19 EPS View

    Glaxo (GSK) beats on earnings and sales in the third quarter. Strong growth of vaccine and respiratory portfolio boosts sales. However, Advair generic severely impacts the drug's U.S. sales.